GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GB Sciences Inc (OTCPK:GBLX) » Definitions » Inventories, Finished Goods

GBLX (GB Sciences) Inventories, Finished Goods : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2003. Start your Free Trial

What is GB Sciences Inventories, Finished Goods?


GB Sciences Inventories, Finished Goods Historical Data

The historical data trend for GB Sciences's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GB Sciences Inventories, Finished Goods Chart

GB Sciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 - - - -

GB Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

GB Sciences Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


GB Sciences Business Description

Traded in Other Exchanges
Address
9205 W. Russell Road, Suite 240, Las vegas, NV, USA, 89148
GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments. The company's intellectual property covers various medical conditions, from which five drug development programs are in the preclinical stage of drug development including its formulations for Parkinson's disease (PD), chronic pain, cytokine release syndrome, depression, and cardiovascular therapeutic programs.
Executives
John C Poss director, officer: Chief Executive Officer
Craig Ellins director, 10 percent owner, officer: CEO 3035 EAST PATRICK LANE, SUITE 9, LAS VEGAS NV 89120
Lazarus Management Co Llc 10 percent owner 260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Israel Opportunities Fund Lllp 10 percent owner C/O IBEX GP LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Investment Partners Lllp 10 percent owner C/O IBEX INVESTORS LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Justin B Borus 10 percent owner 260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206

GB Sciences Headlines

From GuruFocus

UPDATE: Gb Sciences Issues Shareholder Letter

By GuruFocusNews GuruFocusNews 03-16-2022